CEO Summary: One of pathology’s greatest challenges is adequate reimbursement for hospital Part A Pathology Services. Over the past two decades, ever more hospitals took steps to reduce or eliminate payment to pathologists for these services. Now several innovative pathology groups are using a performance-based strategy to negotiate win-win Part A Pathology Service contracts with
Tag: pathology reimbursement
CEO SUMMARY: Change is notoriously slow in both the hospital and the clinical laboratory industry. The announcement of a revamped laboratory joint venture between Houston’s Memorial Hermann Healthcare System and Dynacare demonstrates that market pressures continue to encourage the rationalization of laboratory services. It doesn’t hurt that this joint venture also expects to post healthy
CEO SUMMARY: Public discussion of pathology income and compensation has been taboo for a good reason: the reality is one of contract cutbacks and declining reimbursement for pathology services. THE DARK REPORT is inviting a select group of astute pathologists to Scottsdale on November 8 to identify, articulate and share winning strategies for the preservation
CEO SUMMARY: Ameripath planned to go public in March. However, the stock market’s significant decline and further evaluation of the company’s business plan caused Wall Street underwriters to defer issuing the stock. Pathologists are curious as to whether AmeriPath’s “employee” business model influenced decisions about the public stock offering.
UNDERWRITERS on Wall Street decided to delay